During the routine tests, it's found that the testing method related to Hemodialysis mentioned in the industry standard YY0598-2006 cannot reflect the real bicarbonate concentration in Hemodialysis. To discuss the reaction principle and its interference factors deeply by studying the assay determination of bicarbonate in Hemodialysis, and it could be cited as reference for amending the quality standard or troubleshooting. The improved way of determining bicarbonate concentration in Hemodialysis is also put up.
Bicarbonates ; analysis ; Dialysis Solutions ; analysis ; standards ; Renal Dialysis ; methods ; standards

This essay introduces a method of determining the dimethylacetamide concentration by gas chromatography in the dialyzer. The clinical dialysis process is simulated. The capillary chromingraphic method is used with the peak area and the external standard method, Optimizing testing conditions of gas chromatography. Therefore, This method shows good sensitivity and good repeatability.
Acetamides ; analysis ; Chromatography, Gas ; methods ; Dialysis ; Dialysis Solutions ; analysis ; Humans

This essay is to present an improvement on the concentration assay for sodium chloride in bicarbonate dialysate.
Bicarbonates ; analysis ; chemistry ; Dialysis Solutions ; analysis ; chemistry ; Sodium Chloride ; analysis

The atom absorption spectrometer is introduced to determine the cation concentrations such as potassium, sodium, calcium and magnesium in the dialysis fluid. They are accurately determined by proper preparation and correct dilution ratio under the optimized measuring conditions. Compared with the current arbitrate methods (EDTA titration determination of calcium and magnesium), it supplements the methods of international and industrial standards for determination of cations.
Calcium ; analysis ; Cations ; analysis ; Dialysis Solutions ; analysis ; chemistry ; Magnesium ; analysis ; Potassium ; analysis ; Sodium ; analysis ; Spectrophotometry, Atomic ; methods

OBJECTIVES: Recent reports have suggested that patients treated by CAPD have a relatively increased risk of death compared to patients undergoing HD, although the cause of this discrepancy is poorly understood. Protein malnutrition is an important risk factor in ESRD. Also, amino acid concentrations, for which the physiological function differs from that of protein, may be an independent risk factor in ESRD. There is no doubt concerning the prevalence of low amino acid levels in both HD and CAPD patients. But the difference in plasma amino acid levels between these two groups has not been well defined. The purpose of this study is to compare plasma amino acid levels between patients with ESRD on HD and CAPD. METHODS: A cross sectional study of overnight fasting plasma amino acid concentrations was performed on 12 CAPD and 45 HD patients with ESRD, matched by age, sex and body mass index. The levels of individual plasma amino acid and TAA, EAA, NEAA and BCAA were compared for the HD and CAPD groups. In order to measure losses during HD and CAPD, amino acid and protein concentrations were measured from 10 dialysates obtained from 10 HD patients and 12 peritoneal dialysis solutions from 12 CAPD patients. RESULTS: All of the measured amino acid concentrations were found to be lower in the CAPD group compared to the HD group. Furthermore, the levels of TAA (2017.3 +/- 781.1 vs. 903.3 +/- 316.1 mumole/L), EAA(1201.8 +/- 492.6 vs. 567.6 +/- 223.2 mumole/L), NEAA(815.5 +/- 308.6 vs. 335.7 +/- 100.2 mumole/L); and BCAA (315.0 +/- 146.0 vs. 145.2 +/- 65.0 mumole/L), were all lower in the CAPD group than in the HD group. The protein loss was 2.0 +/- 0.2 g/L in the peritoneal dialysate but was not detectable in the hemodialysates. TAA loss over a one week period was about 61.8 +/- 13.0mmole for the HD group and 38.0 +/- 13.0 mmole for the CAPD group. CONCLUSIONS: Our results show that amino acid concentrations are lower in ESRD patients on CAPD than on HD. It seems likely that protein loss in the peritoneal dialysate is a contributing factor to lowered plasma amino acid concentrations in ESRD patients on CAPD than on HD. We believe that the lowered amino acid concentrations observed in CAPD patients may worsen the clinical outcome compared to HD patients.
Adult ; Amino Acids/blood* ; Amino Acids/analysis ; Comparative Study ; Dialysis Solutions/chemistry ; Female ; Human ; Kidney Failure, Chronic/therapy* ; Kidney Failure, Chronic/blood* ; Male ; Middle Age ; Peritoneal Dialysis, Continuous Ambulatory/adverse effects* ; Renal Dialysis*/adverse effects

OBJECTIVETo investigate the variety of vitro recovery of amino acids for microdialysis probe after different dialysis time in vivo.

METHODSProbes were dialyzed in the amino acids standard solutions with microdialysis system,amino acid standard solutions and the microdialysate of probe were detected by the method of precolumn derivation with HPLC-RF.

RESULTAfter using different time of probe made by regenerated cellulose membrane, the vitro recoveries of Asp, Glu and GABA were not completely same (Asp: F=19.669, P=0.000; Glu: F=103.955, P=0.000; GABA: F=3.454, P=0.040); while the vitro recovery of Tau had no obvious difference(F=2.001, P=0.152). After using 6 h in vivo, recovery remain percentage (RRP) of Asp, Glu,Tau and GABA was 64.34 %, 67.36%, 103.11 % and 98.23 %, respectively, the recoveries of Asp, Glu decreased obviously (Asp: P < 0.01,Glu: P <0.05). After using 12 h in vivo, the RRP of Asp, Glu, Tau and GABA was 43.44 %, 24.42%, 77.45 % and 67.36 %, respectively, the recoveries of Asp, Glu and GABA decreased obviously (Asp: P < 0.001, Glu: P < 0.001, GABA: P < 0.05). After using 24 h in vivo, the RRP of Asp, Glu,Tau and GABA was 36.26 %, 12.24 %, 89.48 % and 71.35 %, respectively, the recoveries of Asp, Glu, GABA decreased obviously (Asp: P < 0.0001, Glu: P < 0.0001, GABA: P < 0.01).

CONCLUSIONDialysis in vivo could lead to the decline of recovery of probe, the decline is more obvious after longer dialysis. So when making brain dialysis experiments, the use time of probe should not be too long. To improve the validity of data, some calibration should be made on the recoveries of probe.

Amino Acids ; analysis ; Animals ; Aspartic Acid ; analysis ; Brain Chemistry ; Chromatography, High Pressure Liquid ; methods ; Dialysis Solutions ; analysis ; Glutamic Acid ; analysis ; Microdialysis ; methods ; Rats ; Rats, Sprague-Dawley ; Time Factors ; gamma-Aminobutyric Acid ; analysis

We examined whether high flux membranes (HF) may induce a greater loss of amino acids compared to low flux membranes (LF). Ten hemodialysis patients participated in this study. Pre- and post-hemodialysis plasma amino acid profiles were measured by reverse-phase high pressure liquid chromatography for both HF and LF. We measured the dialysate amino acid losses during hemodialysis. The reduction difference for plasma total amino acid (TAA), essential amino acid (EAA), and branch chained amino acid (BCAA) was not significantly different in comparisons between the two membranes. (HF vs. LF; TAA 66.85+/-30.56 vs. 53.78+/-41.28, p=0.12; EAA 14.79+/-17.16 vs. 17.97+/-28.69, p=0.12; BCAA 2.21+/-6.08 vs. 4.16+/-10.98 mg/L, p=0.13). For the HF, the reduction in plasma amino acid levels for TAA and EAA were statistically significant. Although it was not statistically significant, the dialysate losses of BCAA were greater than the reduction in plasma (plasma reduction vs. dialysate loss; HF 2.21+/-6.08 vs. 6.58+/-4.32, LF 4.16+/-10.98 vs. 7.96+/-3.25 mg/L). HF with large pores and a sieving coefficient do not influence dialysate amino acid losses. Hemodialysis itself may influence the dialysate amino acid losses and may have an effect on protein metabolism.
Adult ; Aged ; Amino Acids/*blood/chemistry ; Bicarbonates/blood ; Blood Urea Nitrogen ; Chromatography, High Pressure Liquid ; Creatine/blood ; Dialysis Solutions/analysis ; Female ; Humans ; Male ; *Membranes, Artificial ; Middle Aged ; Potassium/blood ; Renal Dialysis/*instrumentation ; Sodium/blood

Cell Line ; Dialysis Solutions ; adverse effects ; Epithelial Cells ; metabolism ; Fibrosis ; Humans ; Peritoneal Dialysis, Continuous Ambulatory ; adverse effects ; Peritoneum ; metabolism ; pathology ; RNA Interference ; RNA, Messenger ; analysis ; RNA, Small Interfering ; pharmacology ; Transforming Growth Factor beta ; antagonists & inhibitors ; genetics ; Transforming Growth Factor beta1

In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n=39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n=41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (-Delta1.2+/-2.9 mL/min/1.73 m2, P=0.027) and urine volume (-Delta363.6+/-543.0 mL/day, P=0.001) during 12 months, but the ICO group did not (-Delta0.5+/-2.7 mL/min/1.73 m2, P=0.266; -Delta108.6+/-543.3 mL/day, P=0.246). Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, beta2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry, ISRCTN23727549]
Adult ; Aged ; CA-125 Antigen/analysis ; Creatinine/urine ; Dialysis Solutions/*therapeutic use ; Female ; Glomerular Filtration Rate ; Glucans/*therapeutic use ; Glucose/*therapeutic use ; Humans ; Interleukin-6/analysis ; Kidney/physiopathology ; Kidney Failure, Chronic/*therapy ; Male ; Membrane Proteins/analysis ; Middle Aged ; Peritoneal Dialysis ; Peritoneal Dialysis, Continuous Ambulatory ; Urea/urine

In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n=39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n=41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (-Delta1.2+/-2.9 mL/min/1.73 m2, P=0.027) and urine volume (-Delta363.6+/-543.0 mL/day, P=0.001) during 12 months, but the ICO group did not (-Delta0.5+/-2.7 mL/min/1.73 m2, P=0.266; -Delta108.6+/-543.3 mL/day, P=0.246). Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, beta2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry, ISRCTN23727549]
Adult ; Aged ; CA-125 Antigen/analysis ; Creatinine/urine ; Dialysis Solutions/*therapeutic use ; Female ; Glomerular Filtration Rate ; Glucans/*therapeutic use ; Glucose/*therapeutic use ; Humans ; Interleukin-6/analysis ; Kidney/physiopathology ; Kidney Failure, Chronic/*therapy ; Male ; Membrane Proteins/analysis ; Middle Aged ; Peritoneal Dialysis ; Peritoneal Dialysis, Continuous Ambulatory ; Urea/urine